L3VLUP
ProSign in

CYTK · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CYTKVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CYTK
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCYTKVRTX
Q3 20205 holders, $114m31 holders, $21.9bn
Q4 20203 holders, $90m30 holders, $18.4bn
Q1 20213 holders, $90m31 holders, $15.4bn
Q2 20212 holders, $74m30 holders, $12.7bn
Q3 20217 holders, $643m35 holders, $10.1bn
Q4 202110 holders, $794m28 holders, $12.4bn
Q1 20226 holders, $624m23 holders, $16.1bn
Q2 202210 holders, $1.0bn25 holders, $18.1bn
Q3 20229 holders, $1.0bn22 holders, $18.4bn
Q4 202212 holders, $1.1bn28 holders, $18.4bn
Q1 202311 holders, $895m26 holders, $21.4bn
Q2 20238 holders, $781m27 holders, $24.7bn
Q3 202310 holders, $753m33 holders, $24.3bn
Q4 202312 holders, $2.4bn32 holders, $28.6bn
Q1 202415 holders, $1.8bn31 holders, $29.8bn
Q2 202416 holders, $1.5bn29 holders, $33.4bn
Q3 202415 holders, $1.5bn27 holders, $33.5bn
Q4 202411 holders, $1.1bn26 holders, $28.5bn
Q1 20259 holders, $544m21 holders, $35.4bn
Q2 20254 holders, $268m21 holders, $32.3bn
Q3 20256 holders, $1.3bn22 holders, $25.9bn
Q4 20258 holders, $1.5bn26 holders, $31.8bn
Q1 202611 holders, $1.5bn25 holders, $31.8bn
Q2 202612 holders, $1.3bn26 holders, $34.6bn
CYTK

Cytokinetics Inc

Holders
11
Reported value
$1.5bn
Buyers
15
Sellers
16

Breadth -1 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CYTK (6)

Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Freestone Grove Partners LP, Moore Capital Management LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC

Only VRTX (20)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →